Complete Filing Data
AN2 Therapeutics, Inc. reported Stockholders Equity of $53.06 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean AN2 Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income * | -$35.2M | -$51.3M | -$64.7M | -$41.0M | -$21.5M |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | $26.0K | -$244.0K | $649.0K | -$347.0K | -$27.0K |
| Research And Development Expense | $24.8M | $40.5M | $54.9M | $28.5M | $16.2M |
| Operating Income Loss | -$38.1M | -$56.8M | -$69.6M | -$42.3M | -$21.6M |
| Operating Expenses | $38.1M | $56.8M | $69.6M | $42.3M | $21.6M |
| Net Income Loss Available To Common Stockholders Basic | -$35.2M | -$51.3M | -$64.7M | -$42.8M | -$28.1M |
| General And Administrative Expense | $13.3M | $14.1M | $14.8M | $12.8M | $4.7M |
| Comprehensive Income Net Of Tax | -$35.1M | -$51.6M | -$64.1M | -$41.3M | -$21.6M |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | $26.0K | -$244.0K | $649.0K | -$347.0K | -$27.0K |
| Other Nonoperating Income Expense | $1.0K | $1.0K | $43.0K | $1.3M | -$38.0K |
| Research And Development Related Party | $1.0M | $750.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$9.4M | -$6.5M | -$10.6M | -$12.7M | -$14.4M | -$16.6M | -$16.7M | -$15.8M | -$15.3M | -$11.3M | -$10.1M | -$7.7M | -$6.9M | -$5.0M | -$2.0M |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | $39.0K | -$23.0K | $17.0K | $139.0K | -$80.0K | -$222.0K | -$3.0K | $56.0K | $199.0K | -$181.0K | -$202.0K | -$131.0K | $3.0K | ||
| Research And Development Expense | $7.0M | $3.2M | $7.7M | $8.3M | $12.1M | $14.7M | $14.4M | $13.5M | $12.0M | $7.4M | $6.7M | $5.6M | $5.3M | $3.9M | $1.6M |
| Operating Income Loss | -$10.0M | -$7.2M | -$11.5M | -$14.0M | -$15.9M | -$18.3M | -$18.2M | -$16.6M | -$16.0M | -$11.8M | -$10.3M | -$7.7M | -$6.9M | -$5.0M | -$2.1M |
| Operating Expenses | $10.0M | $7.2M | $11.5M | $14.0M | $15.9M | $18.3M | $18.2M | $16.6M | $16.0M | $11.8M | $10.3M | $7.7M | $6.9M | $5.0M | $2.1M |
| Net Income Loss Available To Common Stockholders Basic | -$9.4M | -$6.5M | -$10.6M | -$12.7M | -$14.4M | -$16.6M | -$16.7M | -$15.8M | -$15.3M | -$11.3M | -$10.1M | -$9.5M | -$8.9M | -$6.9M | -$2.8M |
| General And Administrative Expense | $3.0M | $4.0M | $3.8M | $3.5M | $3.7M | $3.6M | $3.8M | $3.1M | $4.1M | $3.3M | $3.6M | $2.1M | $1.6M | $898.0K | $401.0K |
| Comprehensive Income Net Of Tax | -$9.3M | -$6.5M | -$10.6M | -$12.6M | -$14.5M | -$16.8M | -$16.7M | -$15.7M | -$15.1M | -$11.5M | -$10.3M | -$7.8M | -$6.9M | -$5.0M | -$2.0M |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | $39.0K | -$23.0K | $17.0K | $139.0K | -$80.0K | -$222.0K | -$3.0K | $56.0K | $199.0K | -$181.0K | -$202.0K | -$131.0K | -$3.0K | $0.00 | |
| Other Nonoperating Income Expense | $1.3M | $0.00 | $1.0K | $1.5M | $797.0K | $716.0K | $431.0K | $213.0K | $28.0K | -$36.0K | -$24.0K | $0.00 | |||
| Research And Development Related Party | $1.0M | $250.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Stockholders Equity | $53.1M | $81.8M | $124.7M | $95.4M | -$47.4M | -$20.3M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $19.9M | $21.4M | $15.6M | $27.2M | $12.1M | $4.1M |
| Retained Earnings Accumulated Deficit | -$241.0M | -$205.8M | -$154.5M | -$89.7M | -$47.4M | |
| Prepaid Expense And Other Assets Current | $1.9M | $2.6M | $3.2M | $2.5M | $1.6M | |
| Liabilities And Stockholders Equity | $62.0M | $92.1M | $138.7M | $102.6M | $65.3M | |
| Liabilities | $8.9M | $10.2M | $14.0M | $7.2M | $3.4M | |
| Employee Related Liabilities Current | $2.4M | $1.7M | $4.0M | $2.2M | $916.0K | |
| Cash And Cash Equivalents At Carrying Value | $19.9M | $21.4M | $15.6M | $27.2M | $12.1M | |
| Available For Sale Securities Debt Securities Current | $38.1M | $62.3M | $91.6M | $68.8M | $46.5M | |
| Assets Current | $59.9M | $86.3M | $110.5M | $98.6M | $60.1M | |
| Assets | $62.0M | $92.1M | $138.7M | $102.6M | $65.3M | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $57.0K | $31.0K | $275.0K | -$374.0K | -$27.0K | |
| Accrued Liabilities Current | $2.1M | $4.5M | $6.7M | $2.8M | $1.4M | |
| Accounts Payable Current | $3.0M | $3.3M | $2.7M | $2.1M | $1.1M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$1.4M | $5.7M | -$11.6M | $15.1M | $8.0M | |
| Accretion Amortization Of Discounts And Premiums Investments | $1.1M | $3.3M | $2.9M | $692.0K | -$53.0K | |
| Other Assets Noncurrent | $0.00 | $804.0K | $1.0M | $720.0K | ||
| Available For Sale Securities Debt Securities Noncurrent | $2.0M | $5.0M | $27.2M | $3.2M | $3.5M | |
| Liabilities Current | $8.7M | $10.2M | $7.2M | $3.4M | ||
| Other Liabilities Current | $1.2M | $791.0K | $666.0K | |||
| Noncash Operating Lease Expense | $53.0K | $77.0K | ||||
| Accretion Or Decrease To Redemption Value And Cumulative Dividends On Preferred Stock | -$1.8M | -$6.5M | ||||
| Preferred Stock Dividends And Other Adjustments | $1.8M | $6.5M | ||||
| Operating Lease Right Of Use Asset Current | $53.0K | $50.0K | ||||
| Accretion To Redemption Value And Cumulative Dividends On Preferred Stock | $1.8M | $6.5M | ||||
| Operating Lease Liability Current | $53.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $60.4M | $68.8M | $73.3M | $87.7M | $98.4M | $110.6M | $139.0M | $87.8M | $82.5M | $105.6M | $115.9M | $115.4M | -$38.3M | -$29.8M | -$23.1M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $18.0M | $18.2M | $20.0M | $33.5M | $26.8M | $24.7M | $32.6M | $40.8M | $26.7M | $28.8M | $40.6M | $82.5M | $15.8M | $27.7M | $82.3M | |
| Retained Earnings Accumulated Deficit | -$232.2M | -$222.9M | -$216.4M | -$198.3M | -$185.5M | -$171.1M | -$137.6M | -$120.9M | -$105.0M | -$77.9M | -$66.5M | -$56.4M | ||||
| Prepaid Expense And Other Assets Current | $2.1M | $4.6M | $2.5M | $4.3M | $2.9M | $2.1M | $2.6M | $2.9M | $1.8M | $2.8M | $3.5M | $1.4M | ||||
| Liabilities And Stockholders Equity | $67.2M | $75.8M | $81.3M | $97.7M | $108.5M | $121.3M | $153.8M | $98.9M | $91.1M | $110.0M | $120.0M | $120.5M | ||||
| Liabilities | $6.9M | $7.0M | $8.0M | $10.0M | $10.1M | $10.7M | $14.8M | $11.2M | $8.6M | $4.4M | $4.2M | $5.1M | ||||
| Employee Related Liabilities Current | $1.7M | $1.2M | $529.0K | $2.1M | $1.8M | $995.0K | $2.2M | $1.6M | $741.0K | $1.1M | $713.0K | $335.0K | ||||
| Cash And Cash Equivalents At Carrying Value | $18.0M | $18.2M | $20.0M | $33.5M | $26.8M | $24.7M | $32.6M | $40.8M | $26.7M | $28.8M | $40.6M | $82.5M | ||||
| Available For Sale Securities Debt Securities Current | $43.9M | $44.7M | $47.1M | $59.9M | $77.8M | $89.5M | $91.2M | $54.4M | $61.8M | $75.6M | $72.8M | $35.8M | ||||
| Assets Current | $64.0M | $67.5M | $69.6M | $97.7M | $107.4M | $116.3M | $126.4M | $98.2M | $90.3M | $107.3M | $116.9M | $119.8M | ||||
| Assets | $67.2M | $75.8M | $81.3M | $97.7M | $108.5M | $121.3M | $153.8M | $98.9M | $91.1M | $110.0M | $120.0M | $120.5M | ||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $64.0K | $25.0K | $48.0K | $112.0K | -$27.0K | $53.0K | -$122.0K | -$119.0K | -$175.0K | -$541.0K | -$360.0K | -$158.0K | ||||
| Accrued Liabilities Current | $2.7M | $3.0M | $4.0M | $4.9M | $5.8M | $6.9M | $6.8M | $6.4M | $4.2M | $1.8M | $1.8M | $2.1M | ||||
| Accounts Payable Current | $2.2M | $2.1M | $3.1M | $1.7M | $1.9M | $2.4M | $4.9M | $3.1M | $3.5M | $1.4M | $1.6M | $2.6M | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$1.4M | $9.0M | -$510.0K | $70.4M | ||||||||||||
| Accretion Amortization Of Discounts And Premiums Investments | $443.0K | $1.1M | $435.0K | -$1.0K | ||||||||||||
| Other Assets Noncurrent | $0.00 | $0.00 | $304.0K | $1.0M | $1.0M | $1.0M | $720.0K | $720.0K | $720.0K | $720.0K | $720.0K | |||||
| Available For Sale Securities Debt Securities Noncurrent | $3.2M | $8.3M | $11.5M | $3.9M | $26.4M | $2.0M | $2.4M | |||||||||
| Liabilities Current | $10.0M | $14.0M | $14.8M | $11.2M | $8.6M | $4.4M | $4.1M | $5.1M | ||||||||
| Other Liabilities Current | $183.0K | $717.0K | $369.0K | $1.3M | $559.0K | $321.0K | $973.0K | |||||||||
| Noncash Operating Lease Expense | $19.0K | $18.0K | ||||||||||||||
| Accretion Or Decrease To Redemption Value And Cumulative Dividends On Preferred Stock | -$1.8M | -$1.9M | -$1.9M | -$761.0K | ||||||||||||
| Preferred Stock Dividends And Other Adjustments | $1.8M | $1.9M | $1.9M | $761.0K | ||||||||||||
| Operating Lease Right Of Use Asset Current | $13.0K | $34.0K | $73.0K | $13.0K | $32.0K | |||||||||||
| Accretion To Redemption Value And Cumulative Dividends On Preferred Stock | $1.8M | $761.0K | ||||||||||||||
| Operating Lease Liability Current | $13.0K | $34.0K | $73.0K | $13.0K | $32.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Share Based Compensation | $6.2M | $8.3M | $8.4M | $4.4M | $974.0K |
| Net Cash Provided By Used In Operating Activities | -$29.8M | -$49.3M | -$53.3M | -$33.5M | -$20.5M |
| Net Cash Provided By Used In Financing Activities | $113.0K | $372.0K | $85.0M | $70.4M | $78.5M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$1.5M | -$807.0K | $1.0M | $1.7M | $1.4M |
| Increase Decrease In Accrued Liabilities | -$2.4M | -$2.2M | $3.8M | $1.7M | $512.0K |
| Increase Decrease In Accrued Compensation | $742.0K | -$2.3M | $1.9M | $1.3M | $490.0K |
| Increase Decrease In Accounts Payable | -$296.0K | $641.0K | $553.0K | $2.5M | $417.0K |
| Net Cash Provided By Used In Investing Activities | $28.3M | $54.6M | -$43.3M | -$21.8M | -$50.0M |
| Proceeds From Sale Maturity And Collections Of Investments | $74.5M | $101.3M | $88.9M | $72.1M | $27.3M |
| Payments To Acquire Investments | $46.2M | $46.8M | $132.2M | $93.8M | $77.3M |
| Proceeds From Stock Options Exercised | $27.0K | $225.0K | $99.0K | $11.0K | |
| Proceeds From Issuance Of Common Stock | $86.0K | $147.0K | $366.0K | ||
| Increase Decrease In Other Current Liabilities | $438.0K | $126.0K | $666.0K | ||
| Increase Decrease In Operating Lease Liability | -$53.0K | -$77.0K | |||
| Proceeds From Issuance Initial Public Offering | $70.4M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|
| Share Based Compensation | $2.0M | $2.4M | $2.1M | $449.0K | $8.0K |
| Net Cash Provided By Used In Operating Activities | -$10.6M | -$17.6M | -$11.6M | -$6.7M | -$1.5M |
| Net Cash Provided By Used In Financing Activities | $65.0K | $349.0K | $199.0K | $63.2M | $79.7M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$645.0K | -$1.1M | -$742.0K | $566.0K | -$102.0K |
| Increase Decrease In Accrued Liabilities | -$411.0K | $233.0K | $1.4M | $64.0K | $332.0K |
| Increase Decrease In Accrued Compensation | -$1.1M | -$3.0M | -$1.4M | -$581.0K | -$316.0K |
| Increase Decrease In Accounts Payable | -$244.0K | -$243.0K | $1.4M | $1.5M | $379.0K |
| Net Cash Provided By Used In Investing Activities | $9.2M | $26.3M | $10.9M | $14.0M | |
| Proceeds From Sale Maturity And Collections Of Investments | $31.5M | $26.3M | $24.9M | $15.0M | |
| Payments To Acquire Investments | $22.3M | $14.0M | $998.0K | ||
| Proceeds From Stock Options Exercised | $27.0K | $225.0K | $10.0K | ||
| Proceeds From Issuance Of Common Stock | $38.0K | $124.0K | $199.0K | ||
| Increase Decrease In Other Current Liabilities | -$422.0K | -$346.0K | |||
| Increase Decrease In Operating Lease Liability | -$19.0K | -$18.0K | |||
| Proceeds From Issuance Initial Public Offering | $63.2M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Diluted EPS * | -$1.16 | -$1.72 | -$2.74 | -$2.79 | -$10.64 |
| Weighted Average Number Of Shares Outstanding Basic | 30.2M | 29.8M | 23.6M | 15.3M | 2.6M |
| Weighted Average Number Of Diluted Shares Outstanding | 30.2M | 29.8M | 23.6M | 15.3M | 2.6M |
| Earnings Per Share Basic | $-1.16 | $-1.72 | $-2.74 | $-2.79 | $-10.64 |
| Common Stock Shares Outstanding | 27.4M | 29.9M | 29.7M | 19.4M | 2.7M |
| Common Stock Shares Issued | 27.4M | 29.9M | 29.7M | 19.4M | 2.7M |
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 500.0M | 17.2M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 0.00 |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Temporary Equity Shares Outstanding | 0.00 | 0.00 | 11.4M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.31 | -$0.21 | -$0.35 | -$0.43 | -$0.48 | -$0.56 | -$0.65 | -$0.81 | -$0.79 | -$0.59 | -$0.53 | -$2.98 | -$3.35 | -$2.62 | -$1.07 |
| Weighted Average Number Of Shares Outstanding Basic | 30.3M | 30.2M | 30.1M | 29.8M | 29.8M | 29.8M | 25.6M | 19.5M | 19.4M | 19.3M | 19.3M | 3.2M | 2.6M | 2.6M | |
| Weighted Average Number Of Diluted Shares Outstanding | 30.3M | 30.2M | 30.1M | 29.8M | 29.8M | 29.8M | 25.6M | 19.5M | 19.4M | 19.3M | 19.3M | 3.2M | 2.6M | 2.6M | |
| Earnings Per Share Basic | $-0.31 | $-0.21 | $-0.35 | $-0.43 | $-0.48 | $-0.56 | $-0.65 | $-0.81 | $-0.79 | $-0.59 | $-0.53 | $-2.98 | $-3.35 | $-2.62 | |
| Common Stock Shares Outstanding | 27.4M | 27.4M | 30.1M | 29.9M | 29.8M | 29.8M | 29.7M | 21.9M | 19.4M | 19.4M | 19.4M | 18.7M | |||
| Common Stock Shares Issued | 27.4M | 27.4M | 30.1M | 29.9M | 29.8M | 29.8M | 29.7M | 21.9M | 19.4M | 19.4M | 19.4M | 18.7M | |||
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | ||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Temporary Equity Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $6.2M | $8.3M | $8.4M | $4.4M | $974.0K |
| Vesting Of Early Exercised Stock Options | $3.0K | $6.0K | $21.0K | $19.0K | |
| Additional Paid In Capital | $294.0M | $287.6M | $278.9M | $185.5M | |
| Stock Issued During Period Value Employee Stock Purchase Plan | $86.0K | $147.0K | $366.0K | ||
| Options Subject To Repurchase Short Term | $2.0K | $6.0K | $17.0K | ||
| Stock Issued During Period Value Stock Options Exercised | $27.0K | $225.0K | $99.0K | ||
| Stock Issued During Period Shares Stock Options Exercised | 63.1K | 28.9K | 15.0K | 0.00 | |
| Options Subject To Repurchase Long Term | $2.0K | $13.0K | |||
| Investment Income Interest | $2.9M | $5.5M | $4.9M | ||
| Investment Income Net | $1.4M | $69.0K | |||
| Stock Issued During Period Value New Issues | $65.5M | ||||
| Stock Issued During Period Value Conversion Of Convertible Securities | $111.1M | ||||
| Repurchase Of Early Exercised Stock Options | $11.0K | ||||
| Repurchase Of Early Exercised Stock Option | $11.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $801.0K | $2.0M | $2.0M | $1.9M | $2.3M | $2.4M | $2.2M | $1.9M | $2.1M | $1.2M | $1.2M | $449.0K | $354.0K | $179.0K | $8.0K |
| Vesting Of Early Exercised Stock Options | $1.0K | $1.0K | $1.0K | $1.0K | $2.0K | $2.0K | $2.0K | $3.0K | $14.0K | $4.0K | $4.0K | $6.0K | |||
| Additional Paid In Capital | $292.6M | $291.7M | $289.7M | $285.8M | $283.9M | $281.6M | $276.6M | $208.7M | $187.7M | $184.0M | $182.8M | $172.0M | |||
| Stock Issued During Period Value Employee Stock Purchase Plan | $48.0K | $38.0K | $23.0K | $124.0K | $167.0K | $199.0K | |||||||||
| Options Subject To Repurchase Short Term | $3.0K | $3.0K | $5.0K | $8.0K | $9.0K | $10.0K | |||||||||
| Stock Issued During Period Value Stock Options Exercised | $27.0K | $225.0K | $99.0K | ||||||||||||
| Stock Issued During Period Shares Stock Options Exercised | 63.1K | 28.9K | 0.00 | 0.00 | |||||||||||
| Options Subject To Repurchase Long Term | $1.0K | $1.0K | $3.0K | $4.0K | $6.0K | ||||||||||
| Investment Income Interest | $687.0K | $754.0K | $888.0K | $1.3M | $1.4M | $1.7M | |||||||||
| Investment Income Net | $466.0K | $228.0K | $27.0K | $25.0K | $15.0K | $2.0K | |||||||||
| Stock Issued During Period Value New Issues | $65.5M | $9.5M | $60.8M | ||||||||||||
| Stock Issued During Period Value Conversion Of Convertible Securities | $111.1M | ||||||||||||||
| Repurchase Of Early Exercised Stock Options | $11.0K | ||||||||||||||
| Repurchase Of Early Exercised Stock Option | $11.0K |
Most recent annual filing with the SEC: March 17, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.